Everything below concerns Reference standard. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-16. Numbers and descriptions here follow the published literature rather than marketing material.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
=== Gut microbiota unaccustomed to endemic organisms === Foodborne illness often occurs as travelers' diarrhea in persons whose gut microbiota is unaccustomed to organisms endemic to the visited region. This effect of microbiologic naïveté is compounded by any food safety lapses in the food's preparation. Locals develop immunity to local food pathogens through repeated exposure, explaining why they often don't get sick from food that affects travelers. This immune adaptation involves developing specific defenses against common local bacteria, viruses, and parasites. Through this process, locals' immune systems produce a measured response that eliminates pathogens without triggering excessive inflammatory reactions, while travelers' immune systems often mount exaggerated responses to novel pathogens.
Freeman's performance generated a positive response; Owen Gleiberman of Entertainment Weekly wrote: "Freeman plays nearly every scene in a doleful hush; he makes you lean in to hear his words, to ferret out the hints of anger and regret that haunt this weary knight." The critic from Variety magazine called Freeman's acting "supremely nuanced". While filming Outbreak, Freeman expressed an interest in starting a film production company. He turned to McCreary, the producer of Bopha!, to be his business partner. Freeman explained that he wanted to achieve representation on screen, explore challenging issues and reveal hidden truths, so they chose to name their firm Revelations Entertainment. A year later, he appeared in Chain Reaction as Paul Shannon, a science-fiction thriller co-starring Keanu Reeves and Rachel Weisz. The film was a critical and commercial disappointment. Next, he was cast opposite Robin Wright in 1996's Moll Flanders, a period drama based on the novel of the same name. The film received a mixed reception; Greg Evans from Variety magazine said Freeman gave a "sweet" performance, while The New York Times critic thought he was miscast.
Treponema pallidum was first microscopically identified in syphilitic chancres by Fritz Schaudinn and Erich Hoffmann at the Charité in Berlin in 1905. Historically, this bacterium was identified in the clinical laboratory through visualization in dark-field microscopy. This bacterium can be detected with special stains, such as the Dieterle stain. T. pallidum is also detected by serology, including nontreponemal VDRL, rapid plasma reagin, treponemal antibody tests (FTA-ABS), T. pallidum immobilization reaction, and syphilis TPHA test.
=== From carboxylic acids and related compounds === Amides are usually prepared by coupling a carboxylic acid with an amine. The direct reaction generally requires high temperatures to drive off the water:
Sources: en.wikipedia.org
=== Singapore === Singapore is an important hub for the passage of oil; it receives crude oil, mostly from the Middle East, and its refineries (most of which are on the 32-square-kilometre (12 sq mi) Jurong Island) produce the products which are then exported around the Asia-Pacific region, processing up to 1.5 million barrels of crude per day. Singapore and Australia made an agreement to keep their energy trade flowing, and Singapore economic officials have said that the country's refineries are maintaining stable operations and drawing on diverse supplies of crude oil.
=== Autobiography === On October 20, 2009, Morgan's autobiography, I Am the New Black, was released. The book includes stories about living in Tompkins Projects in Bed-Stuy, Brooklyn, to becoming a cast member on Saturday Night Live. Morgan appeared on National Public Radio's Fresh Air hosted by Terry Gross, at times becoming very emotional about his former life in a New York ghetto.
== Signs and symptoms == The most common sign of nickel allergy is inflammation of the skin at an area that comes into regular contact with nickel. This often takes the form of a reddened patch of skin with raised bumps (papules) or small blisters (vesicles), and edema. People with chronic dermatitis tend to have dry, scaly, and cracked skin at the site of contact. These sites of inflammation (called "primary eruptions") can occur anywhere on the skin that contacts nickel, but are most common on the hands, face, or anywhere that contacts metal objects such as jewelry or metal clothes buttons. Particularly high levels of nickel exposure can cause irritated patches of skin to appear at other sites on the body (called "secondary eruptions"). These typically occur as blistering rashes on the hands, eyelids, and at the inside of flexing joints (inside the elbow, back of the knee, etc.). Ingestion of nickel may cause a systemic reaction, which can result in generalized inflammation of the skin across the body, small blisters in the hands, irritation inside the flexing joints (flexural eczema), and redness and irritation of both buttocks. Systemic contact dermatitis (SCD) is defined as a dermatitis occurring in an epi-cutaneously contact-sensitized person when exposed to haptens systemically such as orally, per rectum, intravesically, transcutaneously, intrauterinely, intravenously, or by inhalation. The pathophysiology of systemic nickel allergy syndrome (SNAS) is not well understood.
Sources: en.wikipedia.org
== History == Coiled-coil research began in 1953 when Dr. Francis Crick first reported on the theory behind the packing formation of α-helices in fibrous proteins at the time, which he proposed to consist of alpha helices composed of heptad repeats, or seven-residue repeats (a-b-c-d-e-f-g), whereby 2 or more alpha helices twist around each other similar to the strands of a rope. In 1972, Dr. Robert Hodges and his colleagues confirmed Dr. Crick's hypothesis upon sequencing tropomyosin, further discovering that the heptad repeat consists of two hydrophobic residues at the a and d positions, which stabilize coiled coils and are their basis for formation. This confirmation formed the basis for designing engineered coiled-coil proteins to further investigate and better understand coiled-coil interactions, structures, functions, oligomerization, and other properties. Later in 1991, Dr. O'Shea and colleagues obtained the first high-resolution image of a two-stranded coiled-coil at a resolution of 1.8Å. Dr. Hodges was the first to suggest the use of coiled coils in a drug delivery system in 1996 when he proposed a two-stage targeting and delivery system based on heterodimerization, whereby a drug would be conjugated to chain 1 and an antibody would be conjugated to chain 2, such that chains 1 and 2 would form a heterodimeric coiled coil.
== Biological Functions == 2,5-DKPs have been shown to play a role in interspecies bacterial quorum sensing. For example, the 2,5-DKP cyclo(Phe-Pro) has been shown to play a role in the regulation of gene expression in multiple different species of bacteria including V. fishceri, V. cholera, Lactobacillus reuteri, Staphylococcus aureus, among others.
=== Symptoms === Symptoms of SNRI overdose, whether it be a mixed drug interaction or the drug alone, vary in intensity and incidence based on the amount of medicine taken and the individuals sensitivity to SNRI treatment. Possible symptoms may include:
Pembrolizumab, sold under the brand name Keytruda, is a humanized monoclonal antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy to treat many types of cancer. It is administered by slow intravenous injection. Common side effects include fatigue, musculoskeletal pain, decreased appetite, itchy skin, diarrhea, nausea, rash, fever, cough, difficulty breathing, constipation, pain, and abdominal pain. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells, allowing the immune system to destroy them. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes. Pembrolizumab was approved for medical use in the United States in 2014. It is on the World Health Organization's List of Essential Medicines. A fixed-dose combination of pembrolizumab and berahyaluronidase alfa, (Keytruda Qlex) was approved for medical use in the United States in September 2025.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.